百利天恒通过聆讯 高盛、摩根大通、中信证券为联席保荐人

Core Viewpoint - The company, Bailitianheng, has successfully passed the listing hearing on the Hong Kong Stock Exchange, with Goldman Sachs, JPMorgan Chase, and CITIC Securities serving as joint sponsors [1] Group 1: Company Overview - The company is focused on addressing unmet clinical needs and possesses leading global capabilities in innovation research and development, clinical development, and production supply in the ADC/GNC/ARC fields of tumor macromolecule therapy [1] Group 2: Product Development - The company has developed Iza-bren, which is the world's first and currently the only EGFR×HER3 bispecific antibody ADC that has entered Phase III clinical trials [1]